ロード中...
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy
BACKGROUND: Tyrosine kinase inhibitors (TKIs) that act against the epithelial growth factor receptor (EGFR) were once widely used in chemotherapy for many human cancers. However, acquired chemoresistance occurred in almost all patients, limiting the clinical application of EGFR-TKI. Thus far, no eff...
保存先:
| 出版年: | J Nanobiotechnology |
|---|---|
| 主要な著者: | , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628454/ https://ncbi.nlm.nih.gov/pubmed/28978341 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12951-017-0302-5 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|